UNSPSC 51123113: Tocainide

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C11H16N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 27DXO59SAN, chemically known as 2-amino-n-(2,6-dimethylphenyl)propionamid but more generally known as tocainide, which bears US NIH Compound Identifier 38945. European Medicines Agency schedules Tocainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11136MIG.

UNSPSC 51123113 Tocainide, a Commodity code, encompasses pharmaceuticals supplied to state and local health systems, emergency services, and public healthcare agencies. State and local governments actually buy tocainide and comparable emergency medications — antiarrhythmics, vasopressors, and other advanced life support drugs — through sealed competitive bidding and cooperative purchasing agreements that specify unit counts, expiration-date requirements, shelf-life warranties, and delivery timelines. Issuing bodies include city fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances coordinating pharmaceutical procurement across multiple states and localities. The City of Tampa and the Texas Health and Human Services Commission represent the active buyer base, with procurement structured around standardized drug nomenclature (National Drug Codes, NDCs) and compliance with FDA, OSHA, and federal accessibility standards.

The code shows recent activity in Florida and Texas, with multistate cooperative purchasing extending to Minnesota and Oregon. Representative opportunities include the City of Tampa's IFB (Bid No. 26P00188) for Advanced Life Support Medications due April 8, 2026, with an estimated contract value of $40,000, soliciting 370 units of Labetalol HCI, 1,810 units of Epinephrine 1:10,000, 330 units of Adenosine 6mg, and 1,020 units of Diltiazem 25mg for Tampa Fire Rescue, with a one-year contract term and two one-year renewal options; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products due March 26, 2026, establishing two-year contracts with authorized wholesalers effective July 1, 2026, evaluated on fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), fee agreement (5 percent), and price competitiveness (75 percent). The Tampa solicitation includes a 5 percent Small Local Business Enterprise (SLBE) bid discount and requires WCAG 2.2 Level AA accessibility documentation and OSHA Safety Data Sheets. Cooperative purchasing agreements impose 3 percent administrative fees and performance penalties of $200 to $1,500 per violation.